


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 405/06, 405/12, 273/01, A61K 31/455, 31/445, 31/40</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/11071</p>
		<p>(43) International Publication Date: 27 March 1997 (27.03.97)</p>
<p>(21) International Application Number: PCT/DK96/00382</p> <p>(22) International Filing Date: 12 September 1996 (12.09.96)</p> <p>(30) Priority Data: 1040/95 19 September 1995 (19.09.95) DK 1041/95 19 September 1995 (19.09.95) DK</p> <p>(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors: HOHLWEG, Rolf; Nybovej 6, DK-3490 Kvistgaard (DK). JØRGENSEN, Tine; Krogh; Helgesvej 6, DK-3650 Ølstykke (DK). ANDERSEN, Knud; Erik; Rytterparken 64, DK-2765 Smørum (DK). OLSEN, Uffe; Bang; Horsbred 111, DK-2625 Vallensbæk (DK). MADSEN, Peter; Ulvehøj 7, DK-2880 Bagsværd (DK). POLIVKA, Zdeněk; Zborovská 23, 150 00 Praha 5 (CZ). KÖNIGOVA, Otylie; Maiselova 19, 110 00 Praha 1 (CZ). MIKSIK, František; Leckova 1521, 140 00 Praha 4 (CZ). KOVANDOVA, Martina; Zábehlická 47, 100 00 Praha 10 (CZ). SILHANKOVA, Alexandra; V Stihlách 1311/3, 142 00 Praha 4 (CZ). SINDLAR, Karel; Olbrachtova 50, 140 00 Praha 4 (CZ).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: NOVEL HETEROCYCLIC COMPOUNDS</p> <p>(57) Abstract</p> <p>A compound of formula (I), wherein R¹ and R² independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and R³ is hydrogen or C₁₋₃-alkyl; and A is C₁₋₃-alkylene; and Y is <u>>CH-</u>, <u>>C=CH-</u>, <u>>CH-O-</u>, <u>>C=N-</u>, <u>>N-CH₂-</u> wherein only the underscored atom participates in the ring system, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Novel heterocyclic Compounds

Field of the Invention

5 The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

10

The invention also relates to the use of the present compounds for the treatment of insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) or ageing, the present compounds knowing to interfere with neuropeptide containing C-fibres and hence inhibit the secretion and circulation of insulin antagonizing peptides like CGRP or amylin.

15

Background of the Invention

The nervous system exerts a profound effect on the inflammatory response. Antidromic stimulation of sensory nerves results in localized vasodilation and increased vascular permeability (Janecso et al. Br. J. Pharmacol. 1967, 31, 138-151) and a similar response is observed following injection of peptides known to be present in sensory nerves. From this and other data it is postulated that peptides released from sensory nerve endings mediate many inflammatory responses in tissues like skin, joint, urinary tract, eye, meninges, gastro-intestinal and respiratory tracts. Hence inhibition of sensory nerve peptide release and/or activity, may be useful in treatment of, for example arthritis, dermatitis, rhinitis, asthma, cystitis, gingivitis, thrombo-phlebitis, glaucoma, gastro-intestinal diseases or migraine.

Further, the potent effects of CGRP on skeletal muscle glycogen synthase activity and muscle glucose metabolism, together with the notion that this peptide is released from the neuromuscular junction by nerve excitation, suggest that CGRP may play a physiological role in skeletal muscle glucose metabolism by directing the phosphorylated glucose away from glycogen storage and into the glycolytic and oxidative pathways (Rossetti et al. Am. J. Physiol. 264, E1-E10, 1993). This peptide may represent an important physiological modulator of intracellular glucose trafficking in physiological conditions, such as exercise, and may also contribute to the decreased insulin action and skeletal muscle glycogen synthase in pathophysiological conditions like NIDDM or ageing-associated obesity

(Melnik et al. Obesity Res. 3, 337-344, 1995) where circulating plasma levels of CGRP are markedly increased. Hence inhibition of release and/or activity of the neuropeptide CGRP may be useful in the treatment of insulin resistance related to type 2 diabetes or ageing.

5

In US Patent No. 4,383,999 and No. 4,514,414 and in EP 236342 as well as in EP 231996 some derivatives of N-(4,4-disubstituted-3-butenyl)azaheterocyclic carboxylic acids are claimed as inhibitors of GABA uptake. In EP 342635 and EP 374801, N-substituted azaheterocyclic carboxylic acids in which an oxime ether group and vinyl ether group forms

10

part of the N-substituent respectively are claimed as inhibitors of GABA uptake. Further, in WO 9107389 and WO 9220658, N-substituted azacyclic carboxylic acids are claimed as GABA uptake inhibitors. EP 221572 claims that 1-aryloxyalkylpyridine-3-carboxylic acids are inhibitors of GABA uptake.


15

In DE 2833892 some 12H-dibenzo[d,g][1,3,6]dioxozocine derivatives are claimed as local anaesthetics or for treatment of parkinsonism.

Description of the Invention

20

The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof of formula I



(I)

25


wherein R^1 and R^2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^3 is hydrogen or C_{1-3} -alkyl; and

30

A is C_{1-3} -alkylene; and
Y is $>\underline{C}H-CH_2-$, $>\underline{C}=CH-$, $>\underline{C}H-O-$, $>\underline{C}=N-$, $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system; and

Z is selected from



wherein n is 1 or 2; and

5 R^{11} is hydrogen or C_{1-6} -alkyl; and

R^{12} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{13} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14} is $-(CH_2)_mOH$ or $-(CH_2)_tCOR^{15}$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and t is 0 or 1 and

10 wherein R^{15} is -OH, NH_2 , -NHOH or C_{1-6} -alkoxy; and

R^{16} is C_{1-6} -alkyl or -B-COR¹⁵, wherein B is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15} is the same as above; and

... is optionally a single bond or a double bond;
or a pharmaceutically acceptable salt thereof.

The compounds of formula I may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or fractional crystallisation of suitable salts.

Preferably, the compounds of formula I exist as the individual geometric or optical isomers.

The compounds according to the invention may optionally exist as pharmaceutically acceptable acid addition salts or - when the carboxylic acid group is not esterified - as pharmaceutically acceptable metal salts or - optionally alkylated - ammonium salts.

Examples of such salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are hereby incorporated by reference.

The term "C₁₋₆-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl and 1,2,2-trimethylpropyl.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a C₁₋₆-alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.

The term "halogen" means fluorine, chlorine, bromine or iodine.

Illustrative examples of compounds encompassed by the present invention include:

2-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine

2,10-Dichloro-12-(2-dimethylamino)ethoxy-12H-dibenzo[d,g][1,3]dioxocine.

2,10-Dichloro-12-(3-dimethylamino)propyl-12H-dibenzo[d,g][1,3]dioxocine

5 2,10-Dichloro-12-(3-dimethylamino-1-methyl)ethoxy-12H-dibenzo[d,g][1,3]dioxocine

3-Chloro-12-(2-dimethylaminopropylidene)-12H-dibenzo[d,g][1,3]dioxocine

3-Chloro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine

10

3-Chloro-12-(3-dimethylamino-1-methylpropylidene)-12H-dibenzo[d,g][1,3]dioxocine

2-Fluoro-12-(3-dimethylamino)propylidene-12H-dibenzo[d,g][1,3]dioxocine

15 2-Methyl-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine

2-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine

3-Chloro-12-(3-(4-methyl-1-piperazinyl)propylidene)-12H-dibenzo[d,g][1,3]dioxocine

20

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid ethyl ester

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)propyl)-3-piperidinecarboxylic acid

25

or a pharmaceutically acceptable salt thereof.

As used herein, the term "patient" includes any mammal which could benefit from treatment of neurogenic pain or inflammation or insulin resistance in NIDDM. The term
30 particularly refers to a human patient, but is not intended to be so limited.

It has been demonstrated that the novel compounds of formula I inhibit neurogenic inflammation which involves the release of neuropeptides from peripheral and central endings of sensory C-fibres. Experimentally this can be demonstrated in animal models of
35 formalin induced pain or paw oedema (Wheeler and Cowan, Agents Actions 1991, 34, 264-269) in which the novel compounds of formula I exhibit a potent inhibitory effect. Compounds of formula I may be used to treat all painful, hyperalgesic and/or inflammatory

conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, i.e.:


Acutely painful conditions exemplified by migraine, postoperative pain, burns, bruises, post-herpetic pain (Zoster) and pain as it is generally associated with acute inflammation;

5 chronic, painful and/or inflammatory conditions exemplified by various types of neuropathy (diabetic, post-traumatic, toxic), neuralgia, rheumatoid arthritis, spondylitis, gout, inflammatory bowel disease, prostatitis, cancer pain, chronic headache, coughing, asthma, chronic pancreatitis, inflammatory skin disease including psoriasis and autoimmune dermatoses, osteoporotic pain.

10

Further, it has been demonstrated that the compounds of general formula I improves the glucose tolerance in diabetic ob/ob mice and that this may result from the reduced release of CGRP from peripheral nervous endings. Hence the compounds of general formula I may be used in the treatment of NIDDM as well as ageing-associated obesity. Experimentally this has been demonstrated by the subcutaneous administration of glucose into ob/ob mice with or without previous oral treatment with a compound of general formula I.

The compounds of formula I may be prepared by the following method:



room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol, for example, for about 0.5 to 6 h.

Compounds of formula II and III may readily be prepared by methods familiar to those skilled in the art.

Under certain circumstances it may be necessary to protect the intermediates used in the above methods e.g. a compound of formula III with suitable protecting groups. The carboxylic acid group can, for example, be esterified. Introduction and removal of such groups is described in "Protective Groups in Organic Chemistry" J.F.W. McOmie ed. (New York, 1973).

Pharmacological Methods

I. Formalin induced pain or paw oedema

Values for *in vivo* inhibition of formalin induced pain or oedema for the compounds of the present invention were assessed in mice essentially by the method of Wheeler-Aceto and Cowan (Agents Action 1991, 34, 265-269).

About 20 g NMRI female mice were injected 20 ml 1% formalin into the left hind paw. The animals were then placed on a heated (31°C) table, and the pain response was scored. After 1 h they were killed and bled. Left and right hind paws were removed and the weight difference between the paws was used as indication of the oedema response of the formalin injected paw.

II. Histamine induced paw oedema

Values for *in vivo* inhibition of histamine induced oedema for the compounds of the present invention were assessed in rats essentially as described by Amann et al. (Europ. J. Pharmacol. 279, 227-231, 1995).

In brief 250-300 g male Sprague-Dawley rats were anaesthetized with pentobarbital sodium, and placed on a 32 degree heated table. Ten minutes later histamine (50 microliter, 3 mg/ml) was injected in the right hind paw and 20 minutes hereafter the paw swelling was determined by water plethysmography (Ugo Basile). Test compounds were administered intraperitoneally at 15 minutes before the anaesthetics.

TABLE 1

Inhibition of histamine induced oedema at 1mg/kg

Example no.	% oedema inhibition
2	52
3	33

III. Reduced release of CGRP

ob/ob female mice, 16 weeks of age, where injected glucose (2g/kg) subcutaneously. At times hereafter blood glucose was determined in tail venous blood by the glucose oxidase method. At the end of the study the animals were decapitated and trunk blood collected. Immunoreactive CGRP was determined in plasma by radio-immuno-assay. Two groups of animals were used. The one group was vehicle treated, whereas the other group received a compound of formula I via drinking water (100 mg/l) for five days before the test.

For the above indications the dosage will vary depending on the compound of formula I employed, on the mode of administration and on the therapy desired. However, in general, satisfactory results are obtained with a dosage of from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of compounds of formula I, conveniently given from 1 to 5 times daily, optionally in sustained release form. Usually, dosage forms suitable for oral administration comprise from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of the compounds of formula I admixed with a pharmaceutical carrier or diluent.

The compounds of formula I may be administered in a pharmaceutically acceptable acid addition salt form or where possible as a metal or a lower alkylammonium salt. Such salt forms exhibit approximately the same order of activity as the free base forms.

This invention also relates to pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof and, usually, such compositions also

contain a pharmaceutical carrier or diluent. The compositions containing the compounds of this invention may be prepared by conventional techniques and appear in conventional forms, for example capsules, tablets, solutions or suspensions.

- 5 The pharmaceutical carrier employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, talc, gelatine, agar, pectin, acacia, magnesium stearate and stearic acid. Examples of liquid carriers are syrup, peanut oil, olive oil and water.
- 10 Similarly, the carrier or diluent may include any time delay material known to the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- If a solid carrier for oral administration is used, the preparation can be tableted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or
- 15 lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- 20 Generally, the compounds of this invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is 1-500 mg/day, e.g. about 100

25 mg per dose, when administered to patients, e.g. humans, as a drug.

A typical tablet which may be prepared by conventional tableting techniques contains

Core:

- | | | |
|----|--|--------|
| 30 | Active compound (as free compound or salt thereof) | 100 mg |
| | Colloidal silicon dioxide (Aerosil®) | 1.5 mg |
| | Cellulose, microcryst. (Avicel®) | 70 mg |
| | Modified cellulose gum (Ac-Di-Sol®) | 7.5 mg |
| 35 | Magnesium stearate | |

Coating:

HPMC	approx.	9 mg
Mywaceti 9-40 T	approx.	0.9 mg

- 5 *Acylated monoglyceride used as plasticizer for film coating.

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral,
10 ophthalmic solution or an ointment, the oral route being preferred.

15

20

25

30

35


EXAMPLES

The process for preparing compounds of formula I and preparations containing them is further illustrated in the following examples, which, however, are not to be construed as
5 limiting.

Hereinafter, TLC is thin layer chromatography and CDCl_3 is deuterio chloroform and DMSO-d_6 is hexadeuterio dimethylsulfoxide. The structures of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to characteristic
10 protons in the title compounds are presented where appropriate. $^1\text{H-NMR}$ shifts (δ_{H}) are given in parts per million (PPM). M.p. is melting point and is given in $^\circ\text{C}$ and is not corrected. Column chromatography was carried out using the technique described by W.C. Still et al, J. Org. Chem. (1978), 43, 2923-2925 on Merck silica gel 60 (Art. 9385). Compounds used as starting materials are either known compounds or compounds which
15 can readily be prepared by methods known per se.

EXAMPLE 1

20 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride



2,2'-Dihydroxybenzophenone (10.0 g, 46.7 mmol) and diiodomethane (13.1 g, 49 mmol) was
25 dissolved in dry dimethylformamide (180 ml). Dried, finely powdered potassium carbonate (9.2 g, 66.7 mmol) was added, and the mixture was heated at 105°C for 16 h. After cooling to room temperature the reaction mixture was poured into ice water (500 ml). The precipitate was collected by filtration after 0.5 h, washed with water on the filter and dissolved in a mixture of ethanol (80 ml) and 4 N sodium hydroxide (20 ml). The solution was stirred at reflux
30 temperature for 1 h, cooled and diluted with water (300 ml). The formed crystalline precipitate

was filtered off, washed with water (50 ml) and dried *in vacuo*, affording 12H-dibenzo[d,g][1,3]dioxocin-2-one as a solid (9.5 g, 90% yield).

M.p. 93-95°C.

5

A solution of cyclopropylmagnesium bromide in dry tetrahydrofuran (prepared from cyclopropylbromide (24.2 g, 0.2 mol), magnesium turnings (4.86 g, 0.2 mol) and dry tetrahydrofuran (70 ml) was placed under an atmosphere of nitrogen. A solution of the above ketone (9.05 g, 40 mmol) in dry tetrahydrofuran (50 ml) was added dropwise. The reaction mixture was stirred at 40°C for 1.5 h, cooled and added to an ice-cold mixture of saturated ammonium chloride (400 ml) and ether (200 ml). The organic layer was separated, the aqueous phase was extracted with ether (50 ml), the combined organic extracts were washed with water (2 x 100 ml) and brine (50 ml), dried over MgSO₄, evaporated *in vacuo* and stripped with toluene (2 x 25 ml) to furnish 11.2 g 12-cyclopropyl-12H-dibenzo[d,g][1,3]dioxocin-12-ol.

15

¹H NMR (200 MHz, CDCl₃) : δ 0.50 (d, 2H); 0.75 (d, 2H); 2.00 (m, 1H); 5.14 (s, 2H); 6.9-7.4 (m, 6H); 7.81 (d, 2H).

To a solution of the above alcohol (6.21 g, 22 mmol) in dry dichloromethane (225 ml) trimethylsilylbromosilane (3.71 g, 24.2 mmol) was added. The reaction mixture was stirred at room temperature for 1 h and poured on an ice-cold saturated sodium hydrogencarbonate solution (75 ml). The organic phase was separated, washed with icewater (2 x 75 ml) and brine (75 ml), dried over MgSO₄ and evaporated *in vacuo*, which afforded 7.95 g of crude 12-(3-bromo-1-propylidene)-12H-dibenzo[d,g][1,3]dioxocine, which was used in the next step without further purification.

25

A mixture of the above crude bromide (1.83 g, 5.5 mmol), ethyl 3-piperidinecarboxylate (0.865 g, 5.5 mmol), dried potassium carbonate (2.28 g, 16.5 mmol), sodium iodide (0.82 g, 5.5 mmol) and 2-butanone (25 ml) was heated at reflux temperature for 3 h. After cooling to room temperature, diethyl ether (50 ml) and water (50 ml) was added to the reaction mixture. The organic layer was separated, washed with water (2 x 50 ml) and made acidic by addition of 2 N hydrochloric acid. The aqueous layer was separated and the organic phase was extracted twice with water (50 ml). The combined aqueous extracts were adjusted to pH 8.5 with a saturated sodium bicarbonate solution and extracted with dichloromethane (2 x 25 ml). The organic extract was washed with water (50 ml) dried over MgSO₄ and evaporated *in vacuo*, which afforded 1-(3-(12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester as a foam (1.66 g, 74%).

35

- The above ester (1.66 g, 4.0 mmol) was dissolved in ethanol (20 ml) and 2 N sodium hydroxide (6.6 ml, 13.2 mmol) was added. The mixture was stirred at room temperature for 1.5 h. The ethanol was evaporated in vacuo and the remainder was diluted with water (25 ml). 1 N
- 5 Hydrochloric acid (17.6 ml) was added and the solution was washed with diethyl ether (25 ml). The aqueous phase was extracted with dichloromethane (3 x 30 ml). The combined organic extracts were dried over MgSO_4 and evaporated in vacuo to afford 1.1 g of the title compound as a foam, which was triturated with ethyl acetate, filtered off and dried.
- 10 M.p. 190-92°C, decomp.

Calculated for $\text{C}_{23}\text{H}_{25}\text{NO}_4$, HCl, 0.25 $\text{C}_4\text{H}_8\text{O}_2$:


C, 65.82%; H, 6.44%; N, 3.20%; Found:

C, 65.76%; H, 6.58%; N, 3.05%.

15

EXAMPLE 2

- (R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid
- 20 hydrochloride



- A mixture of 12-(3-bromo-1-propylidene)12H-dibenzo[d,g][1,3]dioxocine (7.90 g, 22 mmol,
- 25 prepared as described in example 1, (R)-3-piperidinecarboxylic acid ethyl ester (L)-tartrate (6.60 g, 22 mmol), dry potassium carbonate (12.2 g, 88 mmol), sodium iodide (3.5 g, 22 mmol) and 2-butanone (100 ml) was heated at reflux temperature for 16 h. After cooling to room temperature, diethyl ether (100 ml) and water (100 ml) was added. The organic layer was separated, washed with water (2 x 50 ml) and made acidic by addition of 2 N hydrochloric acid.
- 30 The aqueous layer was separated and the organic phase was extracted twice with water (50 ml).

The combined aqueous extracts were adjusted to pH 8.5 with a saturated sodium bicarbonate solution and extracted with dichloromethane (2 x 25 ml). The organic extract was washed with water (50 ml) dried over MgSO_4 and evaporated *in vacuo*. The resulting residue (6.21 g) was purified by chromatography on silica gel using a mixture of toluene and ethyl acetate as eluent to give (R)-1-(3-(12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester as an oil (3.96 g, 41 %).

The above ester (3.06 g, 7.5 mmol) was dissolved in ethanol (40 ml) and 2 N sodium hydroxide (12.4 ml, 24.8 mmol) was added. The mixture was stirred at room temperature for 1.0 h. The ethanol was evaporated *in vacuo* and the remainder was diluted with water (25 ml). The pH was adjusted to 6 by addition of 1 N hydrochloric acid and the solution was washed with diethyl ether (25 ml). The aqueous phase was extracted with dichloromethane (3 x 30 ml). The combined organic extracts were dried over MgSO_4 and evaporated *in vacuo* to afford 2.75 g of a foam, which was dissolved in tetrahydrofuran (75 ml). Dropwise addition of excess hydrogen chloride in ether afforded the title compound as crystals, which were filtered off and dried (2.65 g, 85 %).

M.p. 227-228 °C, decomp.

Calculated for $\text{C}_{23}\text{H}_{23}\text{NO}_4$, HCl:
C, 66.42%; H, 6.30%; N, 3.37%; Found:
C, 66.50%; H, 6.61%; N, 3.14%.

EXAMPLE 3

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester hydrochloride


(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester (0.86 g, 2.1 mmol, prepared as described in example 2) was dissolved in tetrahydrofuran (10 ml) and a 2.6 N solution of hydrogen chloride in ether (0.97 ml, 2.52 mmol) was added dropwise. The solution was evaporated *in vacuo* and the remainder was treated with ether (20 ml). The precipitate was filtered off, washed with ether and dried *in vacuo*, affording the title compound as a powder.

Calculated for $C_{25}H_{29}NO_4$, HCl, 0.5 H_2O :
C, 66.29%; H, 6.90%; N, 3.09%; Found:
C, 65.97%; H, 7.03%; N, 2.87%.

5

EXAMPLE 4

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid
10 hydrochloride.



15 A mixture of 12-(3-bromo-1-propylidene)-12H-dibenzo[d,g][1,3]dioxocine (4.0 g, 12 mmol, prepared as described in example 1), 4-piperidinecarboxylic acid ethyl ester (1.9 g, 12 mmol), anhydrous potassium carbonate (5.0 g) and sodium iodide (0.2 g) in N,N-dimethylformamide (40 ml) was heated at 60-70°C for 5 h. After cooling, the inorganic salts were filtered off and washed with benzene (40 ml), and the filtrate was diluted with
20 additional benzene (120 ml). The benzene solution was washed with water (3 x 50 ml), dried over $MgSO_4$ and evaporated *in vacuo*. The oily residue (4.8 g) was purified by chromatography on silica gel using a mixture of benzene and ethyl acetate as eluent to give 1-(3-(12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid ethyl ester as an oil (2.3 g, 47%).

25

The above ester (2.30 g, 5.6 mmol) was dissolved in ethanol (30 ml), a 20% solution of sodium hydroxide (3.5 ml) was added and the mixture was stirred at room temperature for 7 h. The solution was diluted with dichloromethane (240 ml) and acidified with concentrated hydrochloric acid (3 ml). The mixture was washed with water (10 ml), the
30 organic phase was dried over $MgSO_4$ and evaporated *in vacuo*. The solid residue was washed with acetone, filtered off and dried *in vacuo*, aff rding the title compound (1.8 g, 73%).

M.p. 239-245°C.


Calculated for $C_{23}H_{25}NO_4$, HCl, 0.5 C_2H_5OH :

C, 65.67%; H, 6.66%; Cl, 8.08%; N, 3.19%; Found:

5 C, 65.51%; H, 6.35%; Cl, 8.78%; N, 3.27%.

EXAMPLE 5

- 10 (R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]-dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride



15

2,2'-Dihydroxy-5,5'-dichlorobenzophenone (12.1 g, 0.042 mol, prepared similarly as described in Journal of the American Chemical Society 77, 543 (1955)) and diiodomethane (11.9 g, 0.044 mol) were dissolved in dry N,N-dimethylformamide (226 ml). Dried and powdered potassium carbonate (8.3 g) was added and the mixture was heated at 105°C for 5 h and left overnight at room temperature. The reaction mixture was poured on ice (220 g). The precipitate was collected by filtration after 0.5 h and dissolved in diethyl ether (500 ml). The organic layer was washed with 5% sodium hydroxide (50 ml), dried over $MgSO_4$, and evaporated *in vacuo*, affording 12 g (96%) of 2,10-dichloro-12H-dibenzo[d,g][1,3]-dioxocin-12-one as a solid.

25

To a solution of cyclopropylmagnesium bromide in dry tetrahydrofuran (prepared from cyclopropylbromide (15.7 g, 0.130 mol), magnesium turnings (3.15 g, 0.130 mol) and dry tetrahydrofuran (45 ml)), a solution of the above ketone (7.65 g, 0.026 mol) in dry tetrahydrofuran (30 ml) was added over 5 minutes with cooling. The reaction mixture was stirred at 38-42°C for 3 h, cooled in an ice-bath, and a mixture of saturated ammonium chloride (260 ml) and diethyl ether (130 ml) was added. The reaction mixture was filtered,

30

- the organic layer was separated, the aqueous phase was extracted with diethyl ether (35 ml). The combined organic extracts were washed with water (2 x 70 ml) and brine (70 ml), dried over MgSO_4 and evaporated in vacuo. The crude product was purified by column chromatography on silica gel (140 g) using benzene as eluent. This afforded 8.75 g (98%) of 2,10-dichloro-12-cyclopropyl-12H-dibenzo[d,g][1,3]dioxocin-12-ol as a solid.
- 5 To a solution of the above alcohol (8.75 g, 0.027 mol) in dry dichloromethane (245 ml) trimethylsilyl bromide (4.02 g, 0.026 mol) was added. The reaction mixture was stirred at room temperature for 1 h and poured on an ice cold saturated sodium hydrogencarbonate solution (80 ml). The organic phase was separated, washed with water (2 x 80 ml) and
- 10 brine (80 ml), dried over MgSO_4 and evaporated in vacuo. This afforded 9.12 g of an oil, which was purified by column chromatography on silica gel (250 g) using a mixture of cyclohexane and benzene (3:1) as eluent. This yielded 6.61 g (62%) of 2,10-dichloro-12-(3-bromo-1-propylidene)-12H-dibenzo[d,g][1,3]dioxocine as an oil which crystallized on standing.
- 15 A mixture of the above bromide (3.0 g, 0.0075 mol), (R)-3-piperidinecarboxylic acid ethyl ester tartrate (3.45 g, 0.0112 mol), dried potassium carbonate (10.35 g, 0.075 mol) and N,N-dimethylformamide (42 ml) was heated at 60°C for 12 h. After cooling to room temperature, water (150 ml) and benzene (75 ml) were added. The organic layer was
- 20 separated, washed with water (3 x 60 ml), dried over MgSO_4 and evaporated in vacuo. The crude oil was purified by column chromatography on silica gel (65 g) using chloroform as eluent. This afforded 1.44 g (40%) of (R)-1-(3-(2,10-dichloro-12H-dibenzo[d,g][1,3]-dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester as an oil.
- 25 The above ester (1.44 g, 0.003 mol) was dissolved in ethanol (25 ml) and 4 N sodium hydroxide (3.36 ml, 0.013 mol) was added. The mixture was left at room temperature overnight. Concentrated hydrochloric acid (1.68 ml), followed by dichloromethane (170 ml) were added, the organic layer was separated, dried over MgSO_4 and evaporated. Evaporation was repeated with dichloromethane (120 ml) and acetone (20 ml). The oily
- 30 residue was dissolved in acetone (10 ml), yielding, after 12 h at room temperature, 0.54 g (37%) of the title compound as crystals.

^1H NMR (250 MHz, DMSO-d_6): δ_{H} 7.49 (d, $J=2.5$ Hz, 1 H); 7.32 (dd, $J=2.5$ Hz and 8.8 Hz, 1 H); 7.26 (dd, $J=2.5$ Hz and 8.8 Hz, 1 H); 7.19 (d, $J=2.5$ Hz, 1 H); 7.09 (d, $J=8.8$ Hz, 1 H); 6.97 (d, $J=8.8$ Hz, 1 H); 6.09 (t, $J=7.2$ Hz, 1 H); 5.84 (s, 2 H); 2.43 (q, $J=7.2$ Hz, 2 H); 3.15 (t, $J=7.2$ Hz).

Calculated for $C_{23}H_{23}Cl_2NO_2$, HCl, 0.5 C_3H_5O :


C, 57.26%; H, 5.30%; N, 2.73%; Cl, 20.70%; Found:

C, 56.95%; H, 5.31%; N, 2.53%; Cl, 20.75%.

5

EXAMPLE 6

10 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid
hydrochloride



- A mixture of 12-(3-bromo-1-propylidene)-12H-dibenzo[d,g][1,3]dioxocine (5.00 g, 15 mmol, prepared as described in example 1), methyl 3-pyrrolidineacetate acetate (3.04 g, 15 mmol), potassium carbonate (6.2 g, 45 mmol) and potassium iodide (2.23 g, 13 mmol) in 2-butanone (70 ml) was heated at reflux temperature for 5 h. The reaction mixture was cooled and water (140 ml) and ether (140 ml) were added. The mixture was vigorously stirred for 5 minutes, the organic layer was separated, washed with water (2 x 50 ml) and dried over $MgSO_4$. The solvent was evaporated *in vacuo* and the residue (4.34 g) was submitted to column chromatography on silica gel (100 g) using a mixture of dichloromethane and methanol (10:1) as eluent. This afforded 1.05 g of 1-(3-(12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid methyl ester.
- 25 To a solution of the above ester (0.85 g, 2.1 mmol) in ethanol (16 ml), 20% sodium hydroxide (1.3 ml) was added, the mixture was stirred at room temperature for 2 h and left to stand overnight. The solution was poured into dichloromethane (100 ml), cooled in an ice bath, acidified with 2 N hydrochloric acid and stirred for 10 minutes. Additional water was added (5 ml). The organic layer was dried over $MgSO_4$, partially decolorized with active charcoal and evaporated *in vacuo*. The hydrochloride of the title compound separated as an amorphous hygroscopic solid (0.64 g, 77%).
- 30

M.p. 70-90°C.

¹H NMR (250 MHz, CDCl₃): δ_H 7.15 (m, 8 H); 5.95 (t, J=7.2 Hz, 1H); 5.85 (s, 2 H);
5 3.36 - 1.51 (bm, 13H).

Calculated for C₂₃H₂₃NO₄, HCl, 0.5 C₂H₆O :


C, 65.67%; H, 6.66%; N, 3.19%; Found:

C, 65.79%; H, 6.59%; N, 3.21%.

10

EXAMPLE 7

1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-
15 pyrrolidineacetic acid hydrochloride



A mixture of 2,10-dichloro-12-(3-bromo-1-propylidene)-12H-dibenzo[d,g][1,3]-dioxocine
20 (4.0 g, 0.01 mol, prepared as described in example 5), 3-pyrrolidineacetic acid methyl ester
acetate (2.23 g, 0.011 mol), potassium carbonate (4.5 g, 0.0325 mol) and sodium iodide
(1.1 g, 7.3 mmol) in 2-butanone (60 ml) was heated at reflux temperature for 6 h. After
cooling to room temperature the reaction mixture was diluted with acetone, filtered and
evaporated *in vacuo*. The crude product was purified by column chromatography on silica
25 gel (200 g), using a mixture of chloroform (95 %) and ethanol (5 %) as eluent. This afforded
0.8 g (17.3 %) of 1-(3-(2,10-dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-
3-pyrrolidineacetic acid methyl ester as an oil.

To the above ester (0.8 g, 1.78 mmol) in ethanol (11.6 ml) a solution of sodium hydroxide
30 (0.288 g) in water (1.08 ml) was added and the reaction mixture was stirred at room
temperature for 16 h. Concentrated hydrochloric acid (1.08 ml) was added followed by
dichloromethane (80 ml). After stirring for 10 minutes the organic layer was separated,

dried over MgSO_4 and evaporated *in vacuo*. The residue was dissolved in acetone (20 ml) and evaporated. The re-evaporation with acetone was repeated twice. The residue was again dissolved in acetone (40 ml) and left at 0°C for 4 h. This afforded 300 mg (36%) of the title compound as a solid.

5

M.p. $183\text{--}193^\circ\text{C}$, decomp.

Calculated for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{NO}_4$, HCl :


C, 56.98%; H, 4.99%; N, 2.89%; Found :

10

C, 56.92%; H, 5.02%; N, 3.16%.

EXAMPLE 8

- 15
- (R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid acetate



- 20
- To a suspension of 12H-dibenzo[d,g][1,3]dioxocin-12-one (9.05 g, 40 mmol) in ethanol (140 ml) a solution of sodium borohydride (0.8 g, 21 mmol) in water (5 ml containing 2 drops of 10% sodium hydroxide) was added dropwise at 40°C and the reaction mixture was stirred at 70°C for 5 h. Additional solid sodium borohydride (1.0 g, 2.6 mmol) was added in small portions and the reaction mixture was heated to 70°C for 2 h. The cloudy
- 25
- solution was filtered and the solvent removed *in vacuo*. Toluene (150 ml) and water (80 ml) were added, the layers were separated, and the aqueous layer was extracted with toluene (50 ml). The combined toluene extracts were washed with water (50 ml), dried over MgSO_4 and evaporated *in vacuo*. The residue (9.03 g), which crystallised after standing was triturated with cyclohexane and filtered off, and the hereby obtained 12H-dibenzo-
- 30
- [d,g][1,3]dioxocin-12-ol was used in next step without further purification.

M.p. 80-90°C.

To a solution of the above alcohol (5.0 g, 22 mmol) in benzene (85 ml) triethylamine (5.5 g, 54 mmol) was added, and a solution of methanesulfonyl chloride (3.2 g, 28 mmol) in benzene (25 ml) was added dropwise at 15-20°C over 20 minutes under cooling on a cold water bath. After addition, the reaction mixture was stirred for 2 h at room temperature. Water (35 ml) was added, and the organic layer was separated, washed with water (25 ml), dried over MgSO_4 and evaporated in vacuo. To the residual oil (5.8 g), anhydrous potassium carbonate (8.6 g, 62 mmol) and 2-bromoethanol (13.6 ml, 191 mmol) were added. The reaction mixture was stirred for 17 h at room temperature, diluted with dichloromethane (60 ml), filtered and evaporated in vacuo. Solid 12-(2-bromoethoxy)-12H-dibenzo[d,g][1,3]dioxocine (5.0 g, 68%) separated from the residue after standing at room temperature and was filtered off and washed with petroleum ether.

M.p. 112-114°C

A solution of the above bromide (1.7 g, 5 mmol), (R)-3-piperidinecarboxylic acid ethyl ester tartrate (2.1 g, 6.7 mmol) and potassium carbonate (1.1 g, 8 mmol) was stirred for 22 h at room temperature. Inorganic salts were filtered off, and the filtrate was diluted with water (130 ml) and extracted with diethyl ether (2 x 40 ml). The organic extracts were washed with water (2 x 20 ml), dried over MgSO_4 and evaporated in vacuo. The oily residue, crude (R)-1-(2-(12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid ethyl ester was used in the next step without further purification.

The above ester (1.6 g, 3.9 mmol) was dissolved in ethanol (16 ml) and 20% sodium hydroxide (2.1 ml) was added. The reaction mixture was stirred at room temperature for 18 h, poured into dichloromethane (320 ml) and acidified with concentrated acetic acid (5.3 ml). The organic phase was washed with water (50 ml), dried over MgSO_4 and evaporated in vacuo. The oily residue was re-evaporated twice with benzene then triturated with acetone to give crystals of the title compound (0.96 g, 55%).


M.p. 120-28°C

Calculated for $\text{C}_{24}\text{H}_{29}\text{NO}_7$:

C, 65.00%; H, 6.59%; N, 3.16%. Found:
C, 65.21%; H, 6.70%; N, 3.06%.

EXAMPLE 9

(R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride



Bis-(5-chloro-2-hydroxyphenyl)methane (25.0 g, 92.9 mmol) was dissolved in N,N-dimethyl formamide (350 ml), and diiodomethane (7.8 ml, 97.5 mmol) and potassium carbonate (18.6 g, 135 mmol) were added. The mixture was heated to 105°C overnight. After cooling, the mixture was poured into icewater (1200 ml). A precipitate was formed immediately. After stirring for 30 minutes, the solid was filtered off and washed with a small amount of water. The solid was suspended in a mixture (80:20) of ethanol and 4 M sodium hydroxide, and the resulting mixture was heated at 80°C for 1 h. After cooling, the mixture was poured into water (600 ml), and the precipitate was filtered off. After drying, this afforded 2,10-dichloro-12H-dibenzo[d,g][1,3]-dioxocine (24.8 g, 95%), which was used for further reaction without purification.

The above dioxocine (7.7 g, 27 mmol) and N-bromosuccinimide (5.4 g, 30 mmol) were suspended in tetrachloromethane (100 ml). Azobisisobutyronitrile (50 mg) was added and the mixture was heated at reflux temperature. During the first 7 h, every second hour, portions of more azobisisobutyronitrile (50 mg) were added. Heating was continued overnight. Two additional portions of azobisisobutyronitrile (50 mg) were then added and heating at reflux temperature was continued for 24 h in total. After cooling, the reaction mixture was filtered and evaporated. Dichloromethane (10 ml) and diethyl ether (15 ml) were added and the solid was filtered off, affording after drying 12-bromo-2,10-dichloro-12H-dibenzo[d,g][1,3]dioxocine (3.37 g, 11%).

The above bromide (3.37 g, 9.36 mmol) was mixed with 2-bromoethanol (8.0 ml, 110 mmol) and potassium carbonate (3.9 g, 28 mmol). The mixture was stirred for 1 h at room temperature. Dichloromethane (10 ml) was added to dilute the mixture, and stirring was

continued overnight at room temperature. The mixture was heated at 120°C for 24 h. After cooling, the mixture was evaporated, and ethyl acetate (100 ml) and water (100 ml) were added. The phases were separated and the organic phase was washed with water (100 ml). The combined aqueous phases were extracted with ethyl acetate (100 ml). The organic extracts were
5 dried (MgSO_4) and evaporated to give crude 12-(2-bromoethoxy)-2,10-dichloro-12H-dibenzo[d,g][1,3]dioxocine (4.34 g). The product was used for further reaction without purification.

The above bromoethoxy compound (4.25 g, 10.5 mmol) was suspended in dimethyl sulfoxide
10 (50 ml). (R)-3-Piperidinecarboxylic acid ethyl ester tartrate (4.1 g, 13.7 mmol) and potassium carbonate (3.2 g, 23 mmol) were added. The reaction mixture was stirred at 50°C overnight. After cooling and filtration, water (250 ml) was added and the mixture was extracted with diethyl ether (2 x 100 ml). The organic extracts were washed with water (75 ml), dried (MgSO_4) and evaporated. The residual oil was purified by column chromatography on silica gel (600 ml)
15 using a mixture of heptane and ethyl acetate (2:1) as eluent. This afforded (R)-1-(2-(2,10-dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid ethyl ester (2.0 g, 40%) as an oil.

The above ester (0.78 g, 1.62 mmol), dissolved in a solution of sodium hydroxide (0.54 g,
20 13.5 mmol) in ethanol (40 ml) and water (5 ml) was stirred at room temperature for 3.5 h. The pH of the mixture was adjusted to 4 by addition of 1 N hydrochloric acid (14 ml). The mixture was extracted with dichloromethane (2 x 60 ml), the combined organic phases were washed with brine (75 ml), dried over MgSO_4 and the solvent was removed *in vacuo*. The residue was stirred with acetone (10 ml) for 2.5 h, the solid product was filtered off and dried, affording the title
25 compound (0.56 g, 71%).

M.p. 218-220°C.


Calculated for $\text{C}_{22}\text{H}_{23}\text{Cl}_2\text{NO}_3$, HCl:

30 C, 54.06%; H, 4.95%; N, 2.87%; Found :
C, 53.9%; H, 4.8%; N, 2.6%.

EXAMPLE 10

35

(R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid hydrochloride



5 A suspension of 2-chloro-12H-dibenzo[d,g][1,3,6]dioxazine (10.65 g, 43 mmol, prepared as described in Journal of Molecular Structures, 131, 1985, 131-140) and 3-chloropropionyl chloride (6.55 g, 51.6 mmol) in dry toluene (100 ml) was heated at reflux temperature for 5 h. After cooling to room temperature, the reaction mixture was washed with a saturated solution of sodium bicarbonate (50 ml). The organic layer was dried (MgSO_4), and evaporated *in vacuo*, which afforded 2-chloro-12-(3-chloropropionyl)-12H-dibenzo[d,g][1,3,6]dioxazine (12.9 g, 88%).

10 A predried flask with lithium aluminium hydride (3.0 g, 79 mmol), suspended in dry tetrahydrofuran (80 ml), was cooled in an ice bath and concentrated sulphuric acid (3.87 g, 39.5 mmol) was added dropwise at a rate to maintain a temperature $< 12^\circ\text{C}$. The solution was stirred at room temperature for 1.5 h. A solution of the above chloride (12.8 g, 37.8 mmol) in dry tetrahydrofuran (80 ml) was added dropwise and stirring was continued for 2 h. The reaction was quenched by careful addition of ethyl acetate (100 ml) followed by water (5.7 ml). Filtration of the mixture and evaporation of the filtrate *in vacuo* afforded 2-chloro-12-(3-chloropropyl)-12H-dibenzo[d,g][1,3,6]dioxazine as a foam.

20 A mixture of the above crude chloride (1.14 g, 3.5 mmol), (R)-3-piperidinecarboxylic acid ethyl ester (L)-tartrate (1.05 g, 3.5 mmol), dried potassium carbonate (1.94 g, 14 mmol), sodium iodide (0.53 g, 3.5 mmol) and 2-butanone (15 ml) was heated at reflux temperature for 60 h. The reaction mixture was filtered, the filtrate washed with 2-butanone (10 ml) and the combined filtrates evaporated *in vacuo*. The crude product was purified by column chromatography on silica gel using a mixture of ethyl acetate and heptane (1:3) containing triethylamine (2.5%) as eluent. This afforded the product, (R)-1-(3-(2-chloro-12H-dibenzo[d,g][1,3,6]dioxazin-12-yl)-1-propyl)-3-piperidinecarboxylic acid ethyl ester (0.77 g, 49%) as an oil.

30 The above ester (0.77 g, 1.73 mmol) was dissolved in ethanol (7.5 ml) and 2 N sodium

hydroxide (2.86 ml, 5.71 mmol) was added. The mixture was stirred at room temperature for 16 h. The ethanol was evaporated in vacuo and the remainder was diluted with water (25 ml). pH was adjusted to 6 by addition of 6 N hydrochloric acid and the aqueous solution was extracted with dichloromethane (3 x 15 ml). The combined organic extracts were dried over
5 MgSO_4 and evaporated in vacuo. The remainder was dissolved in tetrahydrofuran (15 ml) and 2.5 N hydrogen chloride in ether (0.59 ml, 1.47 mmol) was added dropwise. Ether (30 ml) was added and the mixture was stirred for 3 h, the precipitate was filtered off and dried, to afford 0.53 g (68%) of the title compound as a powder.

10 M.p. 177-180°C.

Calculated for $\text{C}_{22}\text{H}_{23}\text{ClN}_2\text{O}_4$, HCl:


C, 58.28%; H, 5.78%; N, 6.18%; Found :

C, 58.3%; H, 5.9%; N, 6.1%.

15

EXAMPLE 11

1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid
20 hydrochloride



25 N-(2-Hydroxyphenyl)formamide (16.0 g, 130 mmol) was dissolved in 99.9% ethanol (65 ml). Sodium methoxide 7.0 g, 130 mmol) was suspended in 99.9% ethanol (70 ml) and added dropwise over 30 minutes. The resulting mixture was stirred for 30 minutes. 1-Bromo-2-chloromethoxybenzene (26.1 g, 118 mmol, synthesis described in J. Heterocycl. Chem., 11, 1974, 331-337) was added dropwise over 15 minutes. The reaction mixture was stirred for 2.5 h
30 at room temperature, heated at reflux temperature for 2 h, and stirred at room temperature overnight. The mixture was filtered and evaporated. The residue was dissolved in toluene (500 ml) and washed with a saturated sodium carbonate solution (2 x 200 ml). The organic phase was

dried (MgSO_4) and evaporated. The residue was suspended in ethanol (40 ml), filtered and washed with ethanol (3 x 10 ml). After drying, this afforded the product, N-(2-(2-bromophenoxy)methoxy)phenyl)formamide (14.1 g, 37%).

- 5 The above formamide (6.8 g, 21 mmol) was suspended in Dowtherm (75 ml), and potassium carbonate (3.9 g, 28 mmol) was added, followed by copper (1.1 g, 17 mmol) and copper bromide (1.5 g, 11 mmol). The reaction mixture was heated at 180°C overnight. After cooling, the mixture was filtered, and the filter cake was washed with dichloromethane. Dowtherm and solvent was distilled off, and ethanol (200 ml) was added to the residue, which was left
- 10 overnight. 4 M Sodium hydroxide (14 ml) was added, and the mixture was heated at reflux temperature for 1 h. After cooling, the mixture was filtered and evaporated. The residue was suspended in ethyl acetate (200 ml) and water (100 ml). The organic phase was washed with water (2 x 75 ml). The aqueous phases were extracted with ethyl acetate (100 ml). The combined organic extracts were evaporated. The residue was suspended in warm cyclohexane
- 15 (100 ml), and left cooling under stirring. The precipitated solid was filtered off, affording after drying the product 12H-dibenzo[d,g][1,3,6]dioxazocine (4.57 g, 50%).

- The above dioxazocine (4.0 g, 19 mmol) was dissolved in dry N,N-dimethylformamide (150 ml). Sodium hydride (1.13 g, 28 mmol, 60% dispersion in oil) was added in portions, and the
- 20 resulting mixture was stirred for 30 minutes at room temperature. 1-Bromo-3-chloropropane (4.6 ml, 47 mmol) was slowly added dropwise, and the reaction mixture was stirred at room temperature overnight. More sodium hydride (0.56 g, 14 mmol) was added, and stirring was continued for 6 h. More sodium hydride (0.56 g, 14 mmol) was added, and stirring was continued overnight. Ammonium chloride (3.2 g) was added, and the mixture was stirred for 30
- 25 minutes. Water was added (300 ml), and the mixture was extracted with dichloromethane (2 x 250 ml). The organic extracts were dried (MgSO_4) and evaporated. The residue was purified by column chromatography on silica gel using a mixture of heptane and ethyl acetate (6:1) as eluent. This afforded the product, 12-(3-chloropropyl)-12H-dibenzo[d,g][1,3,6]dioxazocine (2.18 g, 40%).

30

- The above chloride (1.0 g, 3.5 mmol) and potassium iodide (3.7 g, 22 mmol) in methyl ethyl ketone (110 ml) was heated at reflux temperature for 4 h. 4-Piperidinecarboxylic acid ethyl ester (0.8 g, 5.2 mmol) was dissolved in methyl ethyl ketone (5 ml) and added, followed by potassium carbonate (1.2 g, 8.6 mmol). The reaction mixture was heated at reflux temperature
- 35 for 48 h. After cooling, the mixture was filtered, the filter cake was washed with methyl ethyl ketone, and the filtrate was evaporated. The residual oil was purified by column chromatography on silica gel (500 ml) using ethyl acetate as eluent. This afforded 1-(3-(12H-dibenzo[d,g]-

[1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid ethyl ester (0.80 g, 57%) as an oil.

The above ester (0.50 g, 1.22 mmol), dissolved in a solution of sodium hydroxide (0.24 g, 6 mmol) in ethanol (30 ml) and water (3 ml) was stirred at room temperature for 3 h. The pH of the mixture was adjusted to 3 by addition of 1 N hydrochloric acid (5 ml). The mixture was extracted with dichloromethane (2 x 40 ml), the combined organic phases were washed with brine (50 ml), dried over MgSO_4 and the solvent was removed in vacuo. The residue was triturated with acetone (20 ml), the solid product was filtered off and dried, affording the title compound in quantitative yield (0.52 g).


M.p. 180-187°C.

Calculated for $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_4$, HCl, 1.25 H_2O :

15 C, 59.85%; H, 6.74%; N, 6.35%; Found :
C, 59.85%; H, 6.60%; N, 6.00%.

CLAIMS

1. A compound of formula I



(I)


wherein R^1 and R^2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and


R^3 is hydrogen or C_{1-3} -alkyl; and

10 A is C_{1-3} -alkylene; and

Y is $>\underline{C}H-CH_2-$, $>\underline{C}=CH-$, $>\underline{C}H-O-$, $>\underline{C}=N-$, $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system; and

Z is selected from





wherein n is 1 or 2; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

R^{12} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{13} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{14} is $-(CH_2)_m-OH$ or $-(CH_2)_t-COR^{15}$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and t is 0 or 1 and

wherein R^{15} is $-OH$, NH_2 , $-NHOH$ or C_{1-6} -alkoxy; and

R^{16} is C_{1-6} -alkyl or $-B-COR^{15}$, wherein B is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and


R^{15} is the same as above; and

$...$ is optionally a single bond or a double bond;

or a pharmaceutically acceptable salt thereof.

2. A compound of formula I

15



(I)


wherein R^1 and R^2 independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^3 is hydrogen or C_{1-3} -alkyl; and

A is C_{1-3} -alkylene; and

Y is $>\underline{\text{C}}\text{H}-\text{CH}_2-$, $>\underline{\text{C}}=\text{CH}-$, $>\underline{\text{C}}\text{H}-\text{O}-$, $>\underline{\text{C}}=\text{N}-$, $>\underline{\text{N}}-\text{CH}_2-$ wherein only the underscored atom participates in the ring system; and

Z is selected from



5

wherein n is 1 or 2; and

R¹¹ is hydrogen or C₁₋₆-alkyl; and

R¹² is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

10 R¹³ is hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R¹⁴ is $-(\text{CH}_2)_m\text{OH}$ or $-(\text{CH}_2)_t\text{COR}^{15}$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and t is 0 or 1 and

wherein R¹⁵ is -OH, NH₂, -NHOH or C₁₋₆-alkoxy; and

R^{16} is C_{1-6} -alkyl or $-B-COR^{15}$, wherein B is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15} is the same as above; and

... is optionally a single bond or a double bond;

or a pharmaceutically acceptable salt thereof, provided that when Y is $>\underline{N}-CH_2-$, R^{16} is C_{3-6} -


5 alkyl or $-B-COR^{15}$.

3. A compound according to claim 1 or 2 wherein R^1 and R^2 independently are hydrogen or halogen.

10 4. A compound according to any one of the preceding claims wherein Y is $>\underline{C}=\underline{CH}-$, $>\underline{CH}-O-$ or $>\underline{N}-CH_2-$ wherein only the underscored atom participates in the ring system.

5. A compound according to any one of the preceding claims wherein Z is selected from

15



6. A compound according to the previous claim wherein R^{14} is $-(CH_2)_tCOR^{15}$ wherein t is 0 or 1 and wherein R^{15} is $-OH$.

20

7. A compound according to any of the claims 1 through 6 selected from the following:

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

25 (R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-piperidinecarboxylic acid ethyl ester;

30 1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-4-piperidinecarboxylic acid;

(R)-1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-

piperidinecarboxylic acid;

1-(3-(12H-Dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

- 5 1-(3-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-ylidene)-1-propyl)-3-pyrrolidineacetic acid;

(R)-1-(2-(12H-Dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;


- 10 (R)-1-(2-(2,10-Dichloro-12H-dibenzo[d,g][1,3]dioxocin-12-yloxy)-1-ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Chloro-12H-dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

- 15 1-(3-(12H-Dibenzo[d,g][1,3,6]dioxazocin-12-yl)-1-propyl)-4-piperidinecarboxylic acid;

or a pharmaceutically acceptable salt thereof.

- 20 8. A method of preparing a compound according to claim 1,
CHARACTERIZED in a compound of formula II



(II)

25

wherein R¹, R², R³, A, and Y are as defined above and W is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate may be reacted with an azaheterocyclic compound of formula III

30

HZ

(III)

wherein Z is as defined above.

9. The use of a compound according to any of the claims 1 through 7 as a medicament.

10. The use of a compound according to any of the claims 1 through 7 for preparing a medicament for the treatment of neurogenic inflammation.
- 5 11. The use of a compound according to any of the claims 1 through 7 for preparing a medicament for the treatment of insulin resistance in NIDDM or ageing.
12. A pharmaceutical composition comprising as active component a compound according to any of the claims 1 through 7 together with a pharmaceutically carrier or diluent.
- 10 13. A pharmaceutical composition suitable for treating neurogenic inflammation comprising an effective amount of a compound according to any of the claims 1 through 7 together with a pharmaceutically acceptable carrier or diluent.
- 15 14. A pharmaceutical composition suitable for treating insulin resistance in NIDDM or ageing comprising an effective amount of a compound according to any of the claims 1 through 7 together with a pharmaceutically acceptable carrier or diluent.
- 20 15. The pharmaceutical composition according to claim 12, 13 or 14 comprising between 0.5 mg and 1000 mg of the compound according to any of the claims 1 through 7 per unit dose.
- 25 16. A method of treating neurogenic inflammation in a subject in need of such treatment comprising administering to said subject an effective amount of a compound according to any of the claims 1 through 7.
- 30 17. A method of treating insulin resistance in NIDDM or ageing in a subject in need of such treatment comprising administering to said subject an effective amount of a compound according to any of the claims 1 through 7.
- 35 18. A method of treating neurogenic inflammation in a subject in need of such treatment comprising administering to said subject a pharmaceutical composition according to claim 13.
- 35 19. A method of treating insulin resistance in NIDDM or ageing in a subject in need of such treatment comprising administering to said subject a pharmaceutical composition according to claim 14.

20. The use of a compound according to any of the claims 1 through 7 for preparing a medicament for the treatment of neurogenic inflammation.
- 5 21. The use of a compound according to any of the claims 1 through 7 for preparing a medicament for the treatment of insulin resistance in NIDDM or ageing.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 96/00382

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 405/06, C07D 405/12, C07D 273/01, A61K 31/455, A61K 31/445, A61K 31/40
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 2833892 C2 (EGYT GY6GYSZERVEGYESZETI GYÁR), 7 August 1986 (07.08.86), see example 2,3,6,7 and 9	1-4,8,9, 12-15
A	--	5-7,10,11, 20,21
X	Acta Biochim. Biophys. Hung., Volume 24, No 1-2, 1989, A. Kálmán et al, "Structure-Activity Relationships of new Muscarinergic Dibenzodioxazocines", page 143 - page 158, see page 145	1-4,8,9, 12-15
A	--	5-7,10,11, 20,21

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

28 November 1996

Date of mailing of the international search report

14-12-1996

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00382

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 3844394 A1 (EGIS GYÓGYSZERGYÁR), 13 July 1989 (13.07.89)	1-4,8,9, 12-15
A		5-7,10,11, 20,21
	--	
X	DE 3643991 A1 (EGIS GYÓGYSZERGYÁR), 25 June 1987 (25.06.87)	1-4,8,9, 12-15
A		5-7,10,11, 20,21
	-- -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00382

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-19
because they relate to subject matter not required to be searched by this Authority, namely:
A method for treatment of the human or animal body by therapy, see rule 39.1
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

5776.9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/DK 96/00382

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-C2- 2833892	07/08/86	AT-B- 363091	10/07/81
		AU-B- 517160	09/07/81
		AU-A- 3839678	31/01/80
		CH-A- 635834	29/04/83
		FR-A,B- 2399417	02/03/79
		GB-A,B- 2001980	14/02/79
		NL-A- 7808124	06/02/79
		SE-B,C- 441828	11/11/85
		SE-A- 7808234	03/02/79
		US-A- 4208410	17/06/80
		US-A- 4229350	21/10/80
DE-A1- 3844394	13/07/89	AU-A- 2763788	06/07/89
		BE-A- 1002696	07/05/91
		CH-A- 677669	14/06/91
		CN-A- 1034926	23/08/89
		FR-A- 2625503	07/07/89
		GB-A,B- 2213480	16/08/89
		GR-B- 1000098	15/03/91
		JP-A- 1213273	28/08/89
		NL-A- 8803218	17/07/89
		SE-A- 8804696	29/12/88
		SU-A- 1641190	07/04/91
		US-A- 4965259	23/10/90
DE-A1- 3643991	25/06/87	AT-B- 394366	25/03/92
		AU-B- 589725	19/10/89
		AU-A- 6676586	25/06/87
		BE-A- 905907	12/06/87
		BG-A- 46004	15/09/89
		CA-A- 1291133	22/10/91
		CH-A,B- 670638	30/06/89
		FR-A- 2592043	26/06/87
		GB-A,B- 2184445	24/06/87
		JP-A- 62158265	14/07/87
		NL-A- 8603236	16/07/87
		SE-B,C- 466399	10/02/92
		SE-A- 8605457	21/06/87
		SU-A- 1470187	30/03/89
		US-A- 4906622	06/03/90